RxDoctor Payments Data

Robert Kuhn, DO

Internal Medicine · Traverse City, MINPI 1104818681

Payments from drug & device makers

$6,361in general payments, 2019–2025

Across 377 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • Novo Nordisk$705
  • AstraZeneca$454
  • Pfizer$452
  • Lilly USA, LLC$340
  • Boehringer Ingelheim$323
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,355100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,361 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$11,369
Medicare patients
49
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol25$30,993
EliquisApixaban29$28,728
JardianceEmpagliflozin18$25,774
TrulicityDulaglutide15$17,283
Atorvastatin Calcium161$2,402
Omeprazole120$1,894
Lisinopril137$1,865
Fentanyl13$1,778
Levothyroxine Sodium97$1,685
Rosuvastatin Calcium81$1,590
Duloxetine Hcl45$1,354
Losartan Potassium68$1,298
Raloxifene Hcl21$1,092
Pravastatin Sodium39$1,085
Amlodipine Besylate104$1,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$454$30,99325 claims
PfizerEliquis$452$28,72829 claims
Boehringer IngelheimJardiance$323$25,77418 claims
Lilly USA, LLCTrulicity$340$17,28315 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$60$36313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →